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Abstract. Lung cancer is a leading cause of mortality and 
despite surgical resection a proportion of patients may develop 
metastatic spread. The detection of circulating tumour cells 
(CTCs) may allow for improved prediction of metastatic 
spread and survival. The current study evaluates the efficacy 
of the ScreenCell® filtration device, to capture, isolate and 
propagate CTCs in patients with primary lung cancer. Prior 
to assessment of CTCs, the present study detected cancer 
cells in a proof-of-principle- experiment using A549 human 
lung carcinoma cells as a model. Ten patients (five males 
and five females) with pathologically diagnosed primary 
non-small cell lung cancer undergoing surgical resection, 
had their blood tested for CTCs. Samples were taken from 
a peripheral vessel at the baseline, from the pulmonary vein 
draining the lobe containing the tumour immediately prior 
to division, a further central sample was taken following 
completion of the resection, and a final peripheral sample 
was taken three days post‑resection. A significant increase 
in CTCs was observed from baseline levels following lung 
manipulation. No association was able to be made between 
increased levels of circulating tumour cells and survival or 
the development of metastatic deposits. Manipulation of 
the lung during surgical resection for non-small cell lung 
carcinoma results in a temporarily increased level of CTCs; 
however, no clinical impact for this increase was observed. 
Overall, the study suggests the ScreenCell® device has the 
potential to be used as a CTC isolation tool, following further 
work, adaptations and improvements to the technology and 
validation of results.
Introduction
Lung cancer continues to be a leading cause of mortality in 
the western world (1). The primary cause of mortality even 
following successful resection of the primary tumour is meta-
static spread (1-2). One major route for lung cancer metastatic 
spread is the movement of displaced cells through the circula-
tion to distant sites (3). Circulating tumour cells (CTCs) are cells 
that shed from the primary tumour and have been detected in 
the peripheral blood of patients with cancer. Previous studies 
have revealed that CTCs are heavily implicated in metastatic 
spread (3-4). Understanding CTC biology has become a funda-
mental part of cancer research, as diagnostic blood assays for 
cancer are an area of growing interest. A number of studies have 
presented evidence of the utility of CTCs as potential cancer 
biomarkers for diagnostic and prognostic purposes, which 
may serve as a minimally invasive ‘liquid biopsy’ for real-time 
diagnosis (5-7). Therefore, the ability to isolate and evaluate 
these CTCs may allow for a new method of cancer staging and 
to predict which patients may exhibit an improved response to 
systemic treatments as opposed to surgical excision alone.
Although blood to the lungs is supplied by the pulmonary 
and bronchial arteries, the bronchial veins account for very 
little venous drainage, with almost all blood returning to 
the heart through the pulmonary veins. This single route for 
venous drainage provides an excellent model for the assess-
ment of CTCs, through sampling blood returning from the 
tumour-bearing lobe to the main circulation. Despite being a 
naturally effective model for the study of CTCs, little is known 
regarding the presence of CTCs in the blood draining from the 
tumour-bearing lobe and their long-term impact on survival.
The aim of the current study was to quantify the concentra-
tion of CTCs in blood obtained from the pulmonary vein and 
from simultaneously assessed peripheral blood in patients with 
detectable lung cancer. Other goals of the present study were to 
determine the association between CTC detection and cancer 
stage, histology, lung manipulation and other clinical param-
eters.
Materials and methods
Cell culture. A549 human lung carcinoma cells (American 
Type Culture Collection, Manassas, VA, USA) were grown 
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in advanced Dulbecco's modified Eagle's medium (DMEM) 
containing high glucose, non-essential amino acids, 
sodium pyruvate, phenol red and no L-glutamine (Gibco; 
Thermo Fisher Scientific, Inc., Waltham, MA, USA). The 
advanced DMEM was further supplemented with 10% (v/v) 
penicillin and streptomycin solution (Invitrogen; Thermo 
Fisher Scientific, Inc.) and 10% (v/v) foetal bovine serum 
(Invitrogen; Thermo Fisher Scientific, Inc.). All cell cultures 
were maintained in a humidified atmosphere in an incubator 
at 37˚C containing 5% CO2, with media being changed every 
48 h to ensure optimal growth.
Patients. Ethical approval was sought and granted for the 
present study from the National Research Ethics Service, now 
the Health Research Authority (reference no. 14/LO/1284). 
Patients awaiting radical resection of primary non-small 
cell carcinoma of the lung were recruited from Harefield 
Hospital (Royal Brompton and Harefield Trust, Middlesex, 
UK) following informed consent.
Ten patients aged between 50 and 84 years old (mean 
age, 64 years old) were enrolled between November 2014 
and June 2015. Five patients were male and five were female. 
Seven patients had a history of heavy cigarette smoking, 
with three having never smoked. Two patients had known, 
although minimal, previous asbestos exposure. No patients 
had received therapeutic or neoadjuvant oncological treat-
ments prior to surgery for lung cancer. Between the patients, 
five tumours were located in the right lung (two upper lobe, 
one middle lobe, 2 lower lobe) and five in the left (3 upper 
lobe, two lower lobe). Eight tumours were identified as adeno-
carcinomas and two as squamous cell carcinomas. Tumours 
were resected at various stages, with three staged at Ia, two 
at Ib, one at IIa, three at IIb and one at IIIa. No patients 
had detectable distant metastatic disease at resection. Nine 
patients underwent a pulmonary lobectomy, with two proce-
dures performed thoracoscopically. One patient underwent 
a planned pneumonectomy. In all cases the pulmonary vein 
was ligated prior to division of pulmonary artery branches 
or bronchus.
All blood samples were taken in the operating theatre 
after the patient was anaesthetised and the process is illus-
trated in Fig. 1. Briefly, the baseline sample was taken from 
a peripheral vein or artery prior to the incision. Following 
intraoperative assessment of surgical resectability, a second 
sample was collected from the pulmonary vein draining the 
lobe-bearing tumour prior to the surgical division of the 
pulmonary vein. When the planned surgical intervention with 
systematic lymph dissection was completed, a third sample 
was collected from the pulmonary vein stump. A final sample 
was obtained three days postoperatively from the peripheral 
vein, together with routine clinical blood sampling.
Processing of blood samples using ScreenCell®. ScreenCell® 
filtration device technology (ScreenCell, Paris, France) was 
utilised as previously described (1). Blood sample processing 
is illustrated in Fig. 1. Briefly, all blood samples were 
collected in 3 ml EDTA bottles, inverted, incubated in 7 ml 
of fixative buffer (ScreenCell, Paris, France) and then filtered 
through the Cytology ScreenCell® device. Filters were then 
separated and captured cells stained with haematoxylin and 
eosin (H&E). All H&E stained slides were then viewed by 
a consultant pathologist and cells manually counted with a 
microscope and documented.
Immuocytochemistry analysis of A549 human lung 
carcinoma cells. A549 human lung carcinoma cells (America 
Type Culture Collection, Manassas, VA, USA) were grown 
in T75 flasks to 90% confluency. For this proof‑of‑principle 
experiment, ~50 A549 cells were inoculated into either 3 ml 
of blood from a healthy volunteer or 3 ml of PBS solution 
with lymphocytes added. In the latter case, ~50 lympho-
cytes were taken from healthy volunteer blood by means of 
density gradient centrifugation. A549 cells were collected 
using the Countess Automated Cell Counter (Invitrogen; 
Thermo Fisher Scientific, Inc.) and stained with trypan blue 
(Invitrogen; Thermo Fisher Scientific, Inc.). Media was aspi-
rated from the cells in the flask, which were then incubated 
with 2 ml of TrypLE™ Express (Invitrogen; Thermo Fisher 
Scientific, Inc.) and manually agitated. The cells were resus-
pended in 3 ml of appropriate media to produce a 5 ml cell 
suspension, of which 1 ml was removed. An equal volume 
of cell suspension was mixed with 0.4% trypan blue stain, 
which is selectively absorbed by dead cells, and applied to 
a Countess™ cell counting chamber slide. Three cell count 
readings were obtained and an average value calculated. 
Approximately 50 cells were then added to PBS or human 
blood. The appropriate volume of cells was washed with 
5 ml of PBS (Invitrogen; Thermo Fisher Scientific, Inc., 
Waltham, MA, USA), and then treated with 4% paraformal-
dehyde on ice for 3 min. The primary antibody used was a 
monoclonal mouse anti-human cytokeratin AE1/3 clone 
(catalogue no., M351529-2; Dako; Agilent Technologies, 
Inc., Santa Clara, CA, USA). A 1:50 dilution was prepared, 
as instructed by the ScreenCell® protocol. The antibody was 
diluted in a solution of Tris-buffered saline (TBS) and 1% 
bovine serum albumin (Invitrogen; Thermo Fisher Scientific, 
Inc.), and 70 µl of antibody solution was added to each filter 
at 4˚C overnight. Following primary antibody incubation, the 
filters were washed twice for 1 min in TBST (1:10 dilution of 
Tween‑20:TBS). Excess liquid was blotted and the filters were 
returned to the humidifying chamber on slides with 70 µl 
of horseradish peroxidase (HRP)-conjugated biotinylated 
anti-mouse secondary antibody at a 1:1,000 dilution (cata-
logue no., K4065; Dako EnVision+ kit; Agilent Technologies, 
Inc.) for 40 min at room temperature. Following secondary 
antibody incubation, filters were washed twice for 1 min in 
TBST, and excess liquid blotted off. A 3,3'-diaminobenzidine 
(DAB) -chromogen solution was mixed (20 µl of DAB to 1 ml 
of DAB solution; Dako EnVision+ kit) and 70 µl of the solu-
tion was added to each filter prior to incubation for 10 min 
at room temperature in the humidifying chamber. This was 
followed by the washing of filters in distilled water for 1 min. 
The filters were then placed on Whatman paper and allowed 
to dry at room temperature for 15 min prior to light micros-
copy of positively stained cancer cells.
Statistical analysis. Captured data was analysed using 
GraphPad prism version 5 (San Diego, CA, USA) with 
significance set at P<0.05.
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Results
Screening for lung carcinoma cells with the ScreenCell® 
filtration device. In order to validate the ScreenCell® filtration 
device, A549 human lung carcinoma cells were utilised, as 
this cell line tests positive for AE1/3. The results of this experi-
ment identified a strong positive AE1/3 cytoplasmic staining 
of inoculated A549 cells, whereas lymphocytes were negative 
for AE1/3 staining and markedly smaller in size (Fig. 2).
Isolation of CTCs from the blood samples of patients with lung 
cancer. Using the ScreenCell® filtration device, CTCs were 
detected in 80% of the initial peripheral preoperative blood 
samples and 100% of the central pulmonary vein blood samples 
taken from the tumour-bearing lobe prior to division (Table I). 
There was a significant increase (P=0.04) in the volume of 
CTCs between the baseline and preligation sampling (Fig. 3). 
Occurring in the majority of patients tested, this finding 
supports the hypothesis that the surgical manipulation of the 
lung, and therefore primary tumour, results in an increased 
CTC concentration in the blood. Following resection, however, 
this volume quickly returned to a level close to the baseline, 
with a range similar to that detected preoperatively (Fig. 3). 
There was no significant change in the volume of CTCs 
between baseline levels and either initial post-surgery concen-
trations (P=0.99) or those three days postoperatively (P=0.5). 
All ten patients, regardless of preoperative levels of CTCs, 
were observed to have tumour cells in their peripheral blood 
three days following resection. Eight patients were identified 
to have large clusters of CTCs (>5 cells) in pulmonary vein 
blood samples following lung manipulation, with a further 
patient having smaller clusters. Five of these patients had no 
detectable clusters in their baseline sample (Fig. 4).
There was no significant difference between the mean 
number of CTCs detected in squamous cell carcinoma or 
adenocarcinoma (P=0.71) and no difference in the mean 
number of CTCs between current smokers, ex-smokers and 
non‑smokers (P=0.89) (data not shown). The number of CTCs 
Figure 2. Microscopy image of AE1/3‑stained A549 cells (magnification, x40). There was strong positive cytoplasmic staining of AE1/3 in the A549 cells 
shown by the deep brown halo around the cells. Lymphocytes were used as a negative control.
Figure 1. Flow diagram of the blood sample collection and staining process used. H&E, haematoxylin and eosin.
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Figure 3. Number of circulating tumour cells at each stage of sampling in patients with lung cancer. *P=0.04. Post op, postoperatively.
Figure 4. Positively haematoxylin and eosin‑stained filters. (A) Stage IA (all staging as per TNM lung cancer staging classification) patient (magnification, 
x20), a single atypical suspicious cell is visible (black arrow). (B) Stage IIA patient (magnification, 40x), a small group (~4) of atypical suspicious cells is 
visible (black arrow). (C) Stage IIB patient (magnification, x40), on the right side of the image a large cluster of atypical cells are visible (circulating tumour 
microemboli). (D) Stage III patient of a large cluster of circulating tumour cells are visible to the right of the image, with a distinctly larger nuclei:cytoplasmic 
ratio, characteristic of malignant cells. The dark black spots across the membrane represent pores on the filter (magnification, x40).
Table I. Number of CTCs detected at each stage of the investigation.
 Number of detected CTCs
 -----------------------------------------------------------------------------------------
Blood sample type Mean, n Range, n Patients, %
Peripheral vessel prior to surgery 22.2 0-100 80
Pulmonary vein draining the tumour-bearing lobe prior to resection 65.1 8-200 100
Pulmonary vein following resection 19.4 0-100 80
Peripheral vessel 3 days post-resection 23.5 2-100 100
CTC, circulating tumour cell.
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collected at any stage of surgery had no correlation with the 
nodal status of the patient, tumour size or overall staging of the 
tumour (data not shown).
At the end of the study, nine patients were alive and 
disease-free. One patient succumbed to heart disease >1 year 
following the surgery. The same patient was identified to have 
a metastatic deposit of lung cancer in the femur prior to death. 
The post-resection pathological staging of this patient's adeno-
carcinoma of the lung was T2bN2 (stage IIIa), the highest 
stage of any of the studied patients. Looking specifically at this 
patient's CTC findings, despite having operatively confirmed 
N2 disease, his baseline CTC count was 0 cells/mm3 (data not 
shown). This rose during lung manipulation to 40 cells/mm3 
at preligation, fell post-resection to 25 cells/mm3. and the 
patient's final blood sample exhibited 3 cells/mm3 (data not 
shown). Although not alone in the increase in CTC count 
from baseline during resection, this patient was one of only 
two patients who had no appreciable circulating tumour cells 
preoperatively. Despite a rise in CTC count, no significant 
association between the late development of distant metastatic 
deposits of the tumour and preoperative, intraoperative or 
postoperative concentrations of CTCs was observed in the 
present study.
Discussion
Metastatic spread is unpredictable and remains poorly 
understood. A well-described and researched area is that 
of tumour cell entry and movement in the general vascula-
ture (2). Migrating tumour cells from the blood are commonly 
referred to as CTCs and have been heavily implicated in the 
development of metastases (8). The underlying mechanisms of 
tumour cell dispersion from the primary tumour are not fully 
understood; however, it has been speculated that even simple 
physical exertion may cause this dispersion (9). As observed in 
the current study, detectable levels of CTCs circulate at rest. To 
this end, the general consensus amongst surgeons is to divide 
the pulmonary vein during resection as an early treatment step.
Several early studies (10-12) indicated that tumour manipu-
lation during surgical resection may contribute to tumour cell 
dispersion into the pulmonary vein, with increased volumes of 
CTCs detected in blood from the pulmonary vein of patients 
who had little or no baseline CTC count (10). However, this 
manipulation is typically essential to perform a resection. In a 
more recent study, which evaluated 42 patient samples, blood 
was collected from the tumour-draining pulmonary vein at 
the end of the surgical procedure and analysed for CTCs (13). 
The authors' concluded that the CTCs appeared to have been 
mobilised as a result of surgery and that this may allow their 
further dissemination (13). The current study supports this 
finding, with 5/10 patients demonstrating a rise in CTC count 
intraoperatively, with two of these patients previously having 
no detectable CTCs at baseline readings.
There was no statistically significant difference found 
in pre- and post-operative levels of lung CTCs, as evaluated 
using the ScreenCell® technique. This lack of increase in the 
concentration of CTCs may be due to the surgical technique 
not dislodging a significant volume of cells, the metastatic 
potential of lung cancer or the sensitivity of the ScreenCell® 
system. A recent study, utilising the CellSearch® method 
(Janssen Diagnostics, LLC, South Raritan, NJ, USA) of cell 
detection, concluded that there was a significant increase in 
the CTC count of pulmonary vein blood following surgical 
manipulation of a tumour (14). These findings are supported 
by the results of the present study.
There are several commercially available systems that use 
a variety of techniques to identify CTCs. The present study 
used a size‑based filtration system produced by ScreenCell®, 
due to its simplicity, speed and the benefit that it eliminates 
any antibody bias that may be introduced by other techniques. 
Hou et al (15) identified a strong correlation between an 
increased CTC count and poor patient survival. The current 
study did not validate these findings for non‑small cell lung 
carcinoma.
The investigation of CTCs is not isolated to lung cancer, 
with the technology being utilised in numerous cancer types. 
Breast cancer was one of the first types of cancer to be inves-
tigated. Multiple studies have found a correlation between a 
high baseline CTC concentration and poor progression-free 
survival (16-19). In addition, reducing the level of breast 
cancer CTCs detectable in the blood has been identified to 
be a good marker of response to treatment, a correlation also 
demonstrated in colorectal cancer (16-19). As demonstrated 
in numerous studies, a more advanced tumour stage has 
been associated with a higher CTC count in the peripheral 
blood (16-19). CTCs are detectable at an early tumour stages at 
varying levels, allowing the potential use of CTC analysis as a 
method for early diagnosis (3,4).
In conclusion, although a significant rise in CTCs was 
detected between the initial sample of peripheral blood taken 
and the operative sample obtained prior to pulmonary vein 
ligation, it was not possible to identify an association between 
CTC count and distant metastatic spread of the tumour. To 
the best of our knowledge, no prior studies have investigated 
the impact of intraoperative dissemination of CTCs into the 
systemic vasculature, for either short-term inflammatory 
responses or long-term patient survival. Although an increase 
in CTC concentration was identified to have no clinical impact 
in the present study, no recommendation can be made at this 
stage. Future studies may study a larger cohort of patients, in 
order to better define the rate of sensitivity and specificity of 
using the ScreenCell® filtration device in patients with lung 
cancer. Moreover, the ScreenCell® filtration device has been 
used successfully for detection of CTCs for breast cancer, in 
addition to head and neck cancer. Therefore, future studies 
using the ScreenCell® filtration device may generate novel data 
on CTC isolation from a wide repertoire of cancer types.
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